FDA Modernization Act 3.0
- Bill Number
- S. 355
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Passed Senate
- Latest Action
- 2025-12-17: Held at the desk.
- Last Updated
- 2026-06-24T17:14:32Z
AI-Generated Summary
Purpose
The FDA Modernization Act 3.0 aims to update federal regulations to support the use of non-animal testing methods (referred to as "nonclinical" tests) in drug development. It ensures that U.S. Food and Drug Administration (FDA) rules align with recent changes to the Federal Food, Drug, and Cosmetic Act (FD&C Act), promoting more modern and flexible approaches to safety testing without relying solely on animal-based methods.
Key Provisions
- Rulemaking Requirement: The Secretary of Health and Human Services (HHS), through the FDA Commissioner, must publish an interim final rule within one year of the Act's enactment. This rule will:
- Amend specific sections of Title 21 of the Code of Federal Regulations (CFR) to replace references to "animal" tests, data, studies, models, and research with broader terms like "nonclinical" equivalents.
- Incorporate the definition of "nonclinical test" from Section 505(z) of the FD&C Act into key CFR sections, including 312.3, 314.3, 315.2, and 601.31.
- Affected CFR Sections: The rule targets over 20 specific sections (e.g., 312.22(c), 314.50(d)(2), 601.35(d)) related to investigational new drugs, new drug applications, and biologics approvals. It also covers any other sections needed for regulatory consistency.
- Immediate Effectiveness: The interim final rule takes effect right away, bypassing the usual requirement to show "good cause" under administrative law (5 U.S.C. § 553(b)), allowing quick implementation.
- Technical Amendment: Adjusts the FD&C Act by redesignating a subsection on clinical trial diversity (previously the second subsection (z)) as subsection (aa) to correct numbering errors from prior laws.
Significant Changes to Existing Law
- Builds on amendments from the Consolidated Appropriations Act, 2023 (Section 3209(a)), which expanded FD&C Act Section 505(i) to recognize non-animal testing alternatives for proving drug safety and effectiveness.
- Shifts FDA regulations from mandating or prioritizing animal testing to allowing a wider range of nonclinical methods (e.g., computer models, cell-based tests, or organ-on-a-chip technologies), while maintaining safety standards.
- No outright ban on animal testing; instead, it provides flexibility for innovative alternatives where scientifically valid.
Potential Impacts
- Government Agencies: The FDA must revise its regulations promptly, potentially streamlining internal processes for drug approvals and reducing administrative burdens related to outdated animal-testing language.
- Citizens and Public Health: Could accelerate drug development by encouraging humane, efficient testing methods, leading to faster access to new treatments. May also reduce ethical concerns over animal use in research.
- International Relations: Aligns U.S. standards with global trends toward reducing animal testing (e.g., in the EU), potentially easing international drug approvals and collaborations in pharmaceuticals.
- No direct fiscal impacts mentioned, but indirect savings for industry and agencies through modernized testing.
Main Stakeholders Affected
- FDA and HHS: Directly responsible for implementing the rule changes.
- Pharmaceutical Companies and Drug Developers: Gain flexibility in nonclinical testing, potentially lowering costs and speeding up innovation.
- Researchers and Scientists: Benefit from broader options for safety data submission in drug trials and applications.
- Animal Welfare Organizations: Positively impacted by reduced reliance on animal testing.
- Patients and Consumers: Indirectly affected through potentially safer, quicker drug approvals using advanced methods.
Notable Legal, Constitutional, or Political Implications
- Legal: Enhances regulatory consistency under the FD&C Act, avoiding conflicts between statutes and rules. The immediate effectiveness of the interim rule streamlines administrative procedures but could invite challenges if stakeholders argue insufficient public input.
- Constitutional: No direct implications; supports executive rulemaking authority under the Administrative Procedure Act while promoting science-based policy.
- Political: Reflects bipartisan support for FDA modernization and animal welfare, continuing a trend from prior acts (e.g., FDA Modernization Act 2.0). May encourage further legislation on ethical testing amid growing public and industry pressure for alternatives to animal research.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (9)
Sen. Schmitt, Eric [R-MO], Sen. King, Angus S., Jr. [I-ME], Sen. Kennedy, John [R-LA], Sen. Whitehouse, Sheldon [D-RI], Sen. Marshall, Roger [R-KS], Sen. Blumenthal, Richard [D-CT], Sen. Paul, Rand [R-KY], Sen. Luján, Ben Ray [D-NM], Sen. Schiff, Adam B. [D-CA]
Recent Actions
- 2025-12-17: Held at the desk.
- 2025-12-17: Received in the House.
- 2025-12-17: Message on Senate action sent to the House.
- 2025-12-16: Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S8794)
- 2025-12-16: Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
- 2025-12-16: Measure laid before Senate by unanimous consent. (consideration: CR S8793-8794)
- 2025-12-16: Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
- 2025-12-16: Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
- 2025-02-03: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-02-03: Introduced in Senate
Bill Versions
- FDA Modernization Act 3.0 — issued 2025-12-17 — PDF (6 pages)
- FDA Modernization Act 3.0 — issued 2025-02-03 — PDF (5 pages)